The goal of this study was to assess the impact of doxycycline PEP on M genitalium, an emerging pathogen among men who have sex with men that has rising rates of antibiotic resistance.
The European Commission on Medical Mycology and International Society for Human and Animal Mycology released clinical guidance and research criteria for managing invasive pulmonary aspergillosis among patients with SARS-CoV-2.
There appears to be a low risk of invasive fungal secondary infection, especially aspergillosis, in patients with SARS-CoV-2-related pneumonia and no underlying immunosuppression.
Investigators analyzed data collected over more than 70 years to estimate the annual global incidence of this severe corneal infection.
The FDA has accepted for filing and granted Priority Review to the NDA for ibrexafungerp (SCY-078; Scynexis) for the treatment of vulvovaginal candidiasis.
Investigators summarized the evidence on the efficacy and adverse effects of antifungal agents in patients with hematological disease or undergoing hematopoietic stem cell transplantation.
Lung transplant recipients who were given antifungal medications prophylactically to prevent invasive fungal infections had lower rates of mortality.
Ibrexafungerp is an investigational oral antifungal agent representing a novel therapeutic class of structurally-distinct glucan synthase inhibitors known as triterpenoids.
The Centers for Disease Control and Prevention conducted a study to assess public familiarity of invasive fungal infections.
Critically ill patients hospitalized with COVID-19 — particularly those who develop ARDS — may also experience an opportunistic aspergillosis superinfection.
